On January 22, 2026, Cowen & Co. reaffirmed its Buy rating on Johnson & Johnson, raising its 12-month price target from $222 to $250. This upgrade reflects Cowen’s optimistic view of J&J’s pharmaceutical innovation pipeline and expected margin expansion. Complementing this, Zacks Investment Research flagged J&J as a medical stock with above-consensus earnings potential, based on its proprietary Earnings ESP tool. Together, these analyst actions signal a growing consensus that J&J’s upcoming quarterly results may exceed current street estimates, reinforcing investor conviction in the stock.

In the fourth quarter of 2025, Johnson & Johnson delivered revenue of $24.56 billion, a 9.1% year-over-year increase, led by double-digit growth in oncology and immunology drugs. Adjusted net earnings rose by more than 8% to $26.2 billion on a full-year basis, with Q4 adjusted EPS of $2.46, topping consensus by three cents. For full-year 2026, management forecasts sales between $100 billion and $101 billion—implying mid-single-digit top-line growth—and adjusted EPS of $11.43 to $11.63, driven by continued momentum from Darzalex, Carvykti and recent MedTech launches.

Johnson & Johnson’s 63-year streak of annual dividend increases underscores its commitment to shareholder returns, with a current yield near 2.4%. Last year’s $19.7 billion in free cash flow more than covered $12.4 billion in dividend payments, enabling the company to maintain a fortress balance sheet. With $20 billion in cash and marketable securities against $48 billion in debt, J&J holds one of the industry’s strongest credit profiles—rated AAA by major agencies—positioning it to fund ongoing R&D investment of $14.7 billion and pursue strategic acquisitions without compromising financial flexibility.